Dicerna Pharmaceuticals Inc

NASDAQ:DRNA   3:59:54 PM EDT
25.33
+0.79 (+3.22%)
Products, Strategic Combinations

Dicerna Announces FDA Acceptance Of Lilly’S Investigational New Drug (IND) Application For First Galxc RNAI Candidate Under Companies’Global Research Collaboration, Licensing Agreement

Published: 11/16/2020 12:46 GMT
Dicerna Pharmaceuticals Inc (DRNA) - Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (ind) Application for First Galxc™ Rnai Candidate Under Companies’ Global Research Collaboration and Licensing Agreement.
Dicerna Pharmaceuticals Inc - Lilly Targeting Initiation of Phase 1 Clinical Trial of Ly3561774 by Year-end 2020.
Dicerna Pharmaceuticals Inc - First Ind Filing Under Collaboration Agreement With Lilly Triggers a $10 Million Milestone Payment to Dicerna.
Dicerna Pharmaceuticals Inc - Eligible to Receive Up to $350 Million in Development and Commercialization Milestones for Each Galxc™ Hepatocyte Target.
Dicerna Pharmaceuticals Inc - Eligible to Receive Up to $355 Million for Each Non-hepatocyte Target.